Policy Notices

• Reminder Regarding Recipient and Applicant Grants Policy Related Inquiries
  (NOT-OD-21-151)
  National Institutes of Health
  

General Notices

• Notice of Information: Guidance Regarding Minimum Level of Effort for NCI-Funded Awards
  (NOT-CA-21-096)
  National Cancer Institute
  

• Solicitation of Nominations for the 2022 National Institute of Neurological Disorders and Stroke (NINDS) Landis Award for Outstanding Mentorship
  (NOT-NS-21-077)
  National Institute of Neurological Disorders and Stroke
  

• Request for Information (RFI): National Institute of Dental and Craniofacial Research (NIDCR) Strategic Plan Fiscal Years 2021-2026
  (NOT-DE-21-007)
  National Institute of Dental and Craniofacial Research
  

Notice of Changes to Funding Opportunities

• Notice of Clarification of Responsiveness to NIAAA RFA-AA-21-002 "SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trial Not Allowed)"
  (NOT-AA-21-039)
  National Institute on Alcohol Abuse and Alcoholism
  

• Notice of Clarification of Responsiveness to NIAAA RFA-AA-21-003 "SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 Clinical Trial Not Allowed)"
  (NOT-AA-21-040)
  National Institute on Alcohol Abuse and Alcoholism
  

• Notice of Clarification of Responsiveness to NIAAA RFA-AA-21-004 "SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trial Not Allowed)"
  (NOT-AA-21-041)
  National Institute on Alcohol Abuse and Alcoholism
  

• Notice of Correction of PAR-21-030, "Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)"
  (NOT-AR-21-022)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  

• Notice of NIAMS Participation in RFA-NS-20-008, "HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Required)"
  (NOT-AR-21-024)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  

• Notice of NIAMS Participation in RFA-NS-20-010, "HEAL Initiative: HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Required)"
  (NOT-AR-21-025)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  

• Notice of Change to Award Budget and Clarification regarding Inclusion of KUH Disciplines for PAR-20-220, Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Training (U2C-Clinical Trial Not Allowed)
  (NOT-DK-21-018)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Change to NOT-EB-20-017, "Notice of Special Interest (NOSI): Synthetic Biology for Biomedical Applications"
  (NOT-EB-21-021)
  National Institute of Biomedical Imaging and Bioengineering
  

• Notice of Early Expiration to NOT-EB-20-022, "Notice of Special Interest (NOSI): Administrative Supplement for Providing Travel Support for Awardees to Attend the Annual NIH Synthetic Biology Consortium Meeting (Admin Supp)"
  (NOT-EB-21-022)
  National Institute of Biomedical Imaging and Bioengineering
  

• Notice of NHLBI Participation in NOT-HD-21-027 "Notice of Special Interest (NOSI): Navigating Pediatric to Adult Health Care: Lost in Transition"
  (NOT-HL-21-021)
  National Heart, Lung, and Blood Institute
  

• Notice of Change in Expiration Date for AHRQ PA-21-266, Patient Safety Learning Laboratories: Advancing Patient Safety through Design, Systems Engineering, and Health Services Research (R18 Clinical Trial Optional)
  (NOT-HS-21-017)
  Agency for Healthcare Research and Quality
  

• Notice of Change to Expiration of PAR-18-894, "Mental Health Research Dissertation Grant to Enhance Workforce Diversity (R36 Independent Clinical Trial Not Allowed)"
  (NOT-MH-21-315)
  National Institute of Mental Health
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Partnership between Research Centers in Minority Institutions (RCMI) and Alcohol Research Centers (U54 Clinical Trial Optional)
  (NOT-AA-21-038)
  National Institute on Alcohol Abuse and Alcoholism
  

Notices of Special Interest

• RESCINDED - Notice of Special Interest (NOSI): International Research Collaboration on Drug Abuse and Addiction Research
  (NOT-DA-21-002)
  National Institute on Drug Abuse
  

• Notice of Special Interest: Advancing Research in Gastrointestinal Dysfunction in People with Neurodevelopmental Disorders
  (NOT-NS-22-003)
  National Institute of Neurological Disorders and Stroke
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

Funding Opportunities

• Technology Development for Single-Molecule Protein Sequencing (R43/R44 Clinical Trial not allowed)
  (PAR-21-247)
  National Human Genome Research Institute
  National Cancer Institute
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): October 1, 2021; June 15, 2022; June 15, 2023 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• NIAID Research Education Program Advancing the Careers of a Diverse Research Workforce (R25 Clinical Trial Not Allowed)
  (PAR-21-258)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): September 10, 2021; January 25, 2022; May 25, 2022; January 25, 2023; May 25, 2023
  
  

• NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional)
  (PAR-21-265)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Standard dates apply The first standard due date for this FOA is September 7, 2021.
  
  

• NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
  (PAR-21-266)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Standard dates apply The first standard due date for this FOA is September 5, 2021.
  
  

• NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
  (PAR-21-267)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Standard dates apply The first standard due date for this FOA is September 7, 2021.
  
  

• Cancer Target Discovery and Development (CTD2) (U01 Clinical Trial Not Allowed)
  (PAR-21-274)
  National Cancer Institute
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed)
  (PAR-21-276)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): Applications for this limited competition FOA will be accepted on a rolling basis, beginning July 16, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Aging Research in Animals (ARIA): Promoting Rigorous Research on Behavioral and Social Processes (R61/R33 Clinical Trial Not Allowed)
  (RFA-AG-22-015)
  National Institute on Aging
  Application Receipt Date(s): October 20, 2021
  
  

• Elucidating the Roles of Transposable Elements in AD/ADRD and Aging (R01 Clinical Trial Not Allowed)
  (RFA-AG-22-021)
  National Institute on Aging
  Application Receipt Date(s): November 02, 2021
  
  

• Primary Care-Based Screening and Intervention Development for Prevention of Abuse in Older and Vulnerable Adults in the Context of Alzheimers Disease and Related Dementias (R61/R33 Clinical Trial Required)
  (RFA-AG-22-024)
  National Institute on Aging
  Application Receipt Date(s): October 20, 2021
  
  

• Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Centers (U54 Clinical Trial Not Allowed)
  (RFA-CA-21-038)
  National Cancer Institute
  Application Receipt Date(s): October 07, 2021
  
  

• Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Data and Resource Coordination Center (CAP-IT DRCC) (U24 Clinical Trial Not Allowed)
  (RFA-CA-21-039)
  National Cancer Institute
  Application Receipt Date(s): October 07, 2021
  
  

• Understanding and Targeting the Pathophysiology of Youth-onset Type 2 Diabetes Clinical Centers (U01 Clinical Trial Not Allowed)
  (RFA-DK-21-002)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 03, 2022
  
  

• Understanding and Targeting the Pathophysiology of Youth-onset Type 2 Diabetes Biostatistics Research Center (U01 Clinical Trial Not Allowed)
  (RFA-DK-21-003)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 03, 2022
  
  

• Continuation of The Collaborative Islet Transplantation Registry (U01 Clinical Trial Not Allowed)
  (RFA-DK-21-013)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): October 20, 2021
  
  

• Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 Clinical Trial Required)
  (RFA-HL-22-014)
  National Heart, Lung, and Blood Institute
  National Center for Advancing Translational Sciences
  National Eye Institute
  National Institute on Aging
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): October 08, 2021
  
  

• Network of the National Library of Medicine All of Us Program Center (U24) (Clinical Trial Optional)
  (RFA-LM-21-002)
  National Library of Medicine
  Application Receipt Date(s): September 17, 2021
  
  

• BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science (R01 Clinical Trial Optional)
  (RFA-MH-21-205)
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Cohort (U54 Clinical Trial Optional)
  (RFA-RM-21-025)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): September 24, 2021